MedKoo Cat#: 206844 | Name: SNS062 analog
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SNS062-analog is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). SNS062-analog was mistakenly listed and sold as SNS-062 by some reagent suppliers. SNS062-analog was reported in patent WO 2011029043 (Sunesis Pharmaceuticals). SNS062-analog showed IC50 of <100 nM, against Bruton's tyrosine kinase (Btk kinase)​. NOTE: SNS-062 (also known as Vecabrutinib, CAT#561137) is a clinical stage drug candidate.

Chemical Structure

SNS062 analog
SNS062 analog
CAS#1270014-40-8 (SNS062 analog)

Theoretical Analysis

MedKoo Cat#: 206844

Name: SNS062 analog

CAS#: 1270014-40-8 (SNS062 analog)

Chemical Formula: C19H21ClN6O

Exact Mass: 384.1465

Molecular Weight: 384.87

Elemental Analysis: C, 59.30; H, 5.50; Cl, 9.21; N, 21.84; O, 4.16

Price and Availability

Size Price Availability Quantity
100mg USD 1,250.00
200mg USD 1,950.00
500mg USD 2,650.00
1g USD 3,450.00
2g USD 5,450.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
1270014-40-8 (SNS062-analog) 1510829-06-7 1947403-49-7
Synonym
SNS062-analog; SNS 062-analog; SNS 062-analog.
IUPAC/Chemical Name
N-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-3-yl)-2-((3-chlorophenyl)amino)acetamide
InChi Key
SPSNKQVUYDXOGY-UHFFFAOYSA-N
InChi Code
InChI=1S/C19H21ClN6O/c20-13-3-1-4-14(9-13)22-10-17(27)25-15-5-2-8-26(11-15)19-16-6-7-21-18(16)23-12-24-19/h1,3-4,6-7,9,12,15,22H,2,5,8,10-11H2,(H,25,27)(H,21,23,24)
SMILES Code
O=C(CNC1=CC(Cl)=CC=C1)NC(CCC2)CN2C3=NC=NC4=C3C=CN4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
BTK mediates signaling through the B-cell receptor, or BCR, which is critical for adhesion, migration, proliferation and survival of normal and malignant B-lineage lymphoid cells. BTK has been well validated as a target for treatment of B-cell malignancies, with a BTK inhibitor approved for relapsed/refractory mantle cell lymphoma, relapsed/refractory chronic lymphocytic leukemia, or CLL, CLL with 17p depletion and Waldenström's macroglobulinemia.
Product Data
Biological target:
SNS062 analog is a potent BTK inhibitor, with an IC50 of <100 nM.
In vitro activity:
To be determined
In vivo activity:
To be determined

Preparing Stock Solutions

The following data is based on the product molecular weight 384.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
To be determined
In vitro protocol:
To be determined
In vivo protocol:
To be determined